New cancer drug candidate SHR-4685 enters first human tests
NCT ID NCT07676903
First seen Jun 30, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with measurable tumors and good organ function are eligible to join.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-4685
- What this could lead to
- If safe and effective, SHR-4685 could become a new treatment option for people with advanced solid tumors.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new PET tracer reveal a key cancer target?